BDRX vs. BPTH, QLGN, CMND, PRFX, NTBL, ATNF, GLMD, DRMA, CNSP, and INM
Should you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Bio-Path (BPTH), Qualigen Therapeutics (QLGN), Clearmind Medicine (CMND), PainReform (PRFX), Notable Labs (NTBL), 180 Life Sciences (ATNF), Galmed Pharmaceuticals (GLMD), Dermata Therapeutics (DRMA), CNS Pharmaceuticals (CNSP), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical preparations" industry.
Biodexa Pharmaceuticals (NASDAQ:BDRX) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and earnings.
Biodexa Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biodexa Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 654.72%. Bio-Path has a consensus price target of $40.00, indicating a potential upside of 1,293.73%. Given Bio-Path's higher probable upside, analysts clearly believe Bio-Path is more favorable than Biodexa Pharmaceuticals.
In the previous week, Bio-Path had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 3 mentions for Bio-Path and 0 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.72 beat Bio-Path's score of 0.00 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.
Bio-Path received 280 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 55.42% of users gave Bio-Path an outperform vote.
Biodexa Pharmaceuticals has higher revenue and earnings than Bio-Path.
Biodexa Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.
Summary
Biodexa Pharmaceuticals beats Bio-Path on 8 of the 12 factors compared between the two stocks.
Get Biodexa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodexa Pharmaceuticals Competitors List
Related Companies and Tools
